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Fostering directly observed treatment in tuberculosis: a program 
manager’s perspective
Introduction
Global Tuberculosis (TB) report (2013) released by the World 
Health Organization (WHO) has revealed that an estimated 
8.6 million people developed TB and 1.3 million died from the 
disease in the year 2012 (1). Globally by 2012, the TB prevalence 
and mortality rate had been reduced by 37% and 45% since 1990 
respectively (1). The coverage of anti-retroviral therapy among 
TB/HIV co-infected patients had gradually increased from 49% 
in 2011 to 57% in 2012 (1). India accounts for the maximum 
number of TB cases worldwide, accounting for almost 26% 
of the global burden (1). Similar trends have been obtained 
for Multi-Drug Resistant (MDR) TB as well, and again India 
is ranked as one among the high-burden countries (1). These 
estimates clearly suggest that the country’s efforts to achieve 
Millennium Development Goal 6 by 2015 have not delivered 
the desired output (1,2). The aim of this study is to explore the 
utility and advantages of Directly Observed Treatment (DOT) 
as an integral component of the Revised National TB Control 
Program (RNTCP) and to identify the potential barriers to 
implementation of DOT, thereby, suggesting interventions to 
advocate DOT across the country. 
The role of RNTCP
In India, the TB prevention and control activities are supervised 
and implemented under the RNTCP, which recognizes that 
implementation of a good quality DOT with Short course 
chemotherapy (DOTS) is the first priority for TB control (2,3). 
The success of DOTS strategy eventually depends on its five 
integral components—political commitment, good quality 
sputum microscopy; DOT; continuous supply of quality assured 
drugs, and accountability (2).
DOT
DOT is the key element in DOTS strategy, in which a DOT 
provider (a trained health worker/community volunteer 
except a family member of the patient) insures and supports 
the patients in consuming their drugs throughout the course 
of treatment (Category I= 6 months; Category II= 8 months; 
Category IV= 24–27 months) (2,3). Considering the long 
duration of treatment, it has been observed that most of the 
patients who do not receive DOT, avoid consuming drugs 
once their symptoms subside (1,2). This eventually facilitates 
drug resistance (MDR-TB or extensively drug-resistant TB) 
and magnifies the problem further as such patients serve as a 
potential source of infection to their contacts (1,2). As it is not 
possible to predict who these patients would be, DOT makes a 
sincere and successful attempt to overcome the barrier of non-
adherence to the treatment (2,3). Studies across the world have 
revealed that adopting DOT in different settings has resulted 
in reduction in the number of cases of bacteriological failure, 
relapse, and acquired drug resistance; decrease in mortality 
rates; early detection of adverse effects, drug intolerance; and 
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improvement in the quality of life of the patients and their 
family members (4–6). Further, contrary results in terms of 
poor outcome have been obtained in the absence of DOT, even 
when the uninterrupted supply of drugs is insured (2,7). 
Barriers to DOT
In an Indian set-up it has been found that almost 70% of 
the people avail services from the private sector (medical 
practitioners/laboratory/radiological investigations), owing to 
which most of them eventually land up in a non-DOT regimen 
(8). In addition, a wide range of potential factors such as strict 
timings of public health sector institutes; social stigma associated 
with the disease; prevalent myths and misconceptions; poor/
absence of networking with the private sector; geographical 
inaccessibility of the government healthcare institutes; lack 
of availability of trained healthcare providers in remote areas; 
deficient community ownership and participation; and poor 
Advocacy Communication and Social Mobilization (ACSM) 
activities, have not allowed the public health sector initiatives 
and innovations to reflect their full impact (1–3,7,8). 
Proposed interventions
In order to meet the country’s vision to achieve the universal 
access of TB care, the RNTCP has launched a “treatment 
adherence scheme” (public-private partnership scheme) in 
which every DOT provider who is willing to undertake the 
initial home visit for address verification and defaulter retrieval 
for missed doses will be given an honorarium of 6.42 US dollars 
for every patient who has completed treatment. However, 
those DOT providers, who only administer treatment, will be 
given an honorarium of 4.01 US dollars per patient. In case of 
MDR-TB treatment, an honorarium of 40.15 US dollars (viz. 
16.06 US dollars for intensive phase and 24.09 US dollars for 
continuation phase) is given for each patient completing the 
treatment (9). RNTCP annual report 2011 has revealed that 
program has involved more than 1900 Non-Government 
Organizations (NGOs) and more than 10,000 private 
practitioners in the public-private mix projects (10). In addition, 
an evidence-based integrated strategy should be formulated for 
addressing the identified barriers which advocates the universal 
administration of DOT. The strategy should emphasize on 
the preparation of a comprehensive streetwise DOT directory 
by health workers at the peripheral health institute level; 
developing partnerships with professional organizations/
non-governmental organizations; need-based execution of 
ACSM activities targeted to appropriate audience; sensitization 
sessions for private medical practitioners to adhere to the 
RNTCP guidelines; encouragement of healthcare providers/
community volunteers to become DOT providers; adequate 
counseling of the patients regarding the nature/duration/
need of adherence and completion of treatment; insuring 
immediate release of honorarium by the program managers/
District tuberculosis officers to acknowledge the support of 
DOT providers toward the program; insuring monitoring of the 
DOT provider and guiding them appropriately; involvement of 
medical colleges—infrastructure, faculties and students; and 
adoption of innovative tools such as videophone to encourage 
administration of DOT (1,2,5,9,11,12). 
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